Citation for published version (APA):
Accepted Manuscript

Immunotherapy-responsive childhood neurodegeneration with systemic and central nervous system inflammation

Mario Sa, Yael Hacohen, Lucy Alderson, WK ‘Kling’ Chong, Glenn Anderson, Thomas S. Jacques, David Neubauer, Elzbieta Szczepanik, Ming Lim, Marios Kaliakatsos

PII: S1090-3798(17)31831-7
DOI: 10.1016/j.ejpn.2018.04.010
Reference: YEJPN 2416

To appear in: European Journal of Paediatric Neurology

Received Date: 9 August 2017
Revised Date: 3 April 2018
Accepted Date: 22 April 2018


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Immunotherapy-responsive childhood neurodegeneration with systemic and central nervous system inflammation.

Mario Sa1, Yael Hacohen1, Lucy Alderson2, WK ‘Kling’ Chong1, Glenn Anderson4, Thomas S Jacques4,5, David Neubauer6, Elzbieta Szczepanik7, Ming Lim8,9, Marios Kaliakatsos1

1. Paediatric Neurology, Great Ormond Street Hospital for Children, London, UK
2. Physiotherapy Department, Great Ormond street Hospital or Children, London, UK
3. Paediatric Neuroradiology, Great Ormond street Hospital or Children, London, UK
4. Department of Histopathology, Great Ormond Street for Children NHS Trust, London, UK
5. Developmental Biology and Cancer Program, UCL Great Ormond Street Institute of Child Health
6. Department of Child, Adolescent & Developmental Neurology, University Children's Hospital, Ljubljana, Slovenia
7. Clinic of Neurology of Children and Adolescents, Institute of Mother and Child, Warsaw, Poland
8. Children’s Neurosciences, Evelina London Children's Hospital @ Guy’s and St Thomas' NHS Foundation Trust, King’s Health Partners Academic Health Science Centre, London, UK
9. Faculty of Life Sciences and Medicine, King’s College London

Corresponding author: Dr Marios Kaliakatsos
Paediatric Neurology, Great Ormond Street Hospital for Children, London, UK.
Email: marios.kaliakatsos@gosh.nhs.uk

Running head: Immunotherapy responsive neurodegeneration
Word Count: 2013 Abstract: 139
Title: 98 characters
References: 11 Figure: 3 Video: 3 Table: 1
Abstract

Subacute neuroregression in association with raised neopterin and overexpression of interferon stimulated genes (ISGs) could indicate a type 1 interferonopathy. Here we describe a novel immunotherapy-responsive, clinico-immunological and imaging phenotype with evidence of innate immune activation. Three children (patient 1: 22-month-old boy; patient 2: 5-year-old girl; patient 3: 4-year-old girl) presented with asymmetric bilateral mixed dystonia and spasticity, regression in language (expressive more than receptive) and bulbar symptoms with no evidence of seizures. Symptoms evolved over several weeks to months. Brain MRI changes mimicked cerebral atrophy, initially asymmetric. CSF revealed raised neopterin. Blood RNA assay showed abnormal overexpression of ISGs and transient raised alanine aminotransferase (ALT). Importantly, all three children were treated with intravenous methylprednisolone and immunoglobulin with significant and sustained improvement in their motor and language function, and normalisation of imaging. Immune-mediated encephalitis can masquerade as subacute neuroregression.
Introduction

Type I interferonopathies are a novel group of multiple monogenic autoinflammatory and autoimmune disorders presenting with early-onset systemic and organ-specific disease and characterized by genetic upregulation of the antiviral type I interferon axis with heterogeneous and expanding phenotypes. To date 18 different causative genes have been identified\(^1\). This was first described as the classical phenotype of Aicardi-Goutières syndrome (AGS), a genetic leukoencephalopathy mimicking a congenital infection and characterized by progressive cerebral atrophy, basal ganglia calcification and lymphocytosis.

Interferons play an important role in the immune response against viral infections. The secretion of these cytokines is normally induced by activation of recognition receptors of the innate immune system after exposure to viral nucleic acids\(^1\). Abnormalities in these test results can also occur in acquired conditions such as autoimmune disorders and viral infections although not typically seen in antibody-mediated encephalopathies\(^2,3\). Until recently, it was difficult to directly measure type 1 interferon (IFN) concentrations in biological samples. IFN activity is determined through IFN signature, meaning the mRNA quantification of genes that are induced by IFN activity - interferon-stimulated genes (ISGs). A neurological syndrome associated with raised neopterin and abnormal activation of ISGs could indicate a type I interferonopathy.\(^2\)

Here, we describe three children who presented with subacute motor and bulbar regression, mildly high alanine aminotransferase (ALT), imaging appearances mimicking cerebral atrophy and an abnormal ISGs who improved with immunotherapy suggestive of an acquired disorder. Written informed consent for publication of the case description and the videos was obtained for all patients.

Case 1:

A previously well 22-month-old boy with a normal antenatal and developmental profile, presented with fluctuating left sided hemiparesis. Five months later, following an intercurrent illness, he developed an additional right-sided weakness and was unable to sit (Video 1). His speech regressed to 5 single words only and he developed swallowing difficulties. There was no history of seizures, behavioural deterioration or sleep problems. On examination, he had mixed dystonia and spasticity with increased tone of all limbs, more marked in the lower limbs. There was sustained clonus on the left. He had increased reflexes bilaterally (left more than right) with up-going plantars. There was mild facial weakness on the left side but full range of ocular movements. Head circumference was normal. There
was no hepatosplenomegaly. Serial magnetic resonance imaging (MRI) of the brain demonstrated progressive initially right hemispheric and subsequently evolving to global symmetric cerebral volume loss (Figure 1-A). At 18 months from clinical presentation he was started on six weekly pulses intravenous Methylprednisolone (IVMP, 30mg/kg/d), followed by six weekly IV Immunoglobulin (IVIG, 2g/kg). IVIG treatment is ongoing. This treatment resulted in improvement mainly in his fine motor and non-verbal communication skills. Although less impressive, he showed improvement in his gross motor skills and speech as well. He is now able to sit unsupported and is slowly gaining new vocabulary (Video 1). Two years after treatment initiation brain MRI showed complete reversal of previous changes and no other abnormalities. (Figure 1-B).

Case 2:
A previously well 5-year-old girl with a normal antenatal and developmental profile, presented with a subacute onset over three months of left sided weakness, frequent falls and difficulties climbing stairs. She was also unable to raise her left arm and had problems dressing and undressing. Her right side was also affected and her handwriting deteriorated. Her speech deteriorated and she developed swallowing difficulties with excessive drooling. There was no cognitive regression, sleep disturbance or history of seizures. On examination, her speech was dysarthric. She had a mixture of spasticity and dystonia with lower limbs more affected than upper limbs and left side more than right. Her tone was increased bilaterally with sustained clonus on the left and upgoing plantars bilaterally. Head circumference was normal. Brain MRI demonstrated generalized volume loss more marked in the right cerebral hemisphere (Figure 1-C). Brain biopsy findings are summarised in Figure 2. At 12 months from onset the patient was treated with four cycles of pulse IVMP (30mg/kg/d for 5 days) and IVIG (2g/kg) three to four months apart. This resulted in significant improvement in her movement disorder and in all domains of function (gross motor, fine motor and speech) (Video 2). Repeated imaging three years after treatment showed normalisation of MRI appearances (Figure 1-D).

Case 3:
A previously well 4-year-old girl with mild gross motor developmental delay (walked independently at the age of 21 months), presented with a progressive one-year history of frequent trips and falls, difficulty climbing stairs, and progressive walking difficulty needing the aid of a wheelchair for outdoors (Video 3). There was also five-month history of speech regression; initially slurred incomprehensible words, followed by complete loss of expressive language. She had dysphagia with choking on solids and liquids and drooling. Behavioural difficulties were also reported with frequent angry outbursts and
peer relationship problems. There was no history of seizures. On examination, her tone was increased in the lower limbs with mixed spasticity and dystonia, right being worse than left and bilateral upgoing plantars. She walked with a wide gait with both her knees hyperextended. There was drooling but no cranial nerve abnormalities. Head circumference was below the 0.4th centile (no previous measurements available for comparison). No hepatosplenomegaly was found. MRI brain showed mild global cerebral volume loss mimicking atrophy (Figure 1-E). At 15 months from onset she had one course of three days IVMP (30mg/kg/d), followed by IVIG (2g/kg) cycles, five courses over 20 months. Marked improvement in her lower limb tone, with gain in both motor and expressive language skills, was observed. A repeat MRI at 13 months after treatment initiation showed reversal of previous changes (Figure 1-F). Currently, she is able to climb stairs unaided (Video 3), her speech is clear and she can produce three to four word sentences.

Investigations, treatment and outcomes for all patients are summarized in Table 1. All 3 patients were investigated for a range of infective, inflammatory and neurometabolic aetiologies, none of which were identified. CSF in all patients showed no cells, normal protein and raised neopterin at 355, 200 and 151nmol/L (normal range 7-65) respectively. Repeated CSF analysis showed normalization of neopterins in patient 2 (29 nmol/L, 24 months after treatment) and reduction in patient 3 (93 nmol/L, 12 months after treatment). Patient 1 did not have CSF neopterins retested after treatment initiation. Oligoclonal bands were negative. Blood RNA assay showed abnormal overexpression of ISGs (Figure 3) and raised ALT (maximum 393U/L patient 2) in all patients. ISGs were repeated in all three patients and have normalized in patients 1 and 2 but remain moderately abnormal in patient 3 (Figure 3). ALT abnormalities eventually normalized in all patients. RNA sequencing for viruses in brain biopsy was negative in patients 1 and 2. Liver and muscle biopsies in patients 1 and 2 revealed no histochemical or enzymatic evidence of mitochondrial disorder. Patient 1 had a low complex IV (0.008; normal range: 0.014-0.034) on respiratory complex enzyme analysis, but mitochondrial DNA sequencing and analysis for mitochondrial DNA deletion/rearrangements was negative.

Genetic testing included whole exome sequencing for patients 1 and 2. This did not show any changes in the genes known to be responsible for interferonopathies, nuclear genes associated mitochondrial disorders, neurotransmitter disorders, early onset parkinsonism, dystonia associated disorders and neurodegeneration with brain iron accumulation. Patient 3 underwent whole genome sequencing also with no abnormalities identified so far (analysis not yet finalised). Testing for antibodies associated with
autoimmune encephalitis and serology screening for infections was negative. All patients had normal electroencephalograms.

Patient’s 2 brother presented at 11 months of age (3 months after his sister’s presentation) with an episode of vomiting and lethargy and was found to have raised ALT of 2000 U/L. The lethargy resolved within 24 hours and he remained neurologically intact. He was also found to have elevated ISGs tested acutely. Both his ALT and ISGs normalized after several months (Figure 3).

Discussion:
We describe three non-related previously well children who presented with a distinct clinical, immunological and imaging phenotype. All patients presented with subacute deterioration in motor function with a mixture of dystonia and spasticity, bulbar symptoms including dysphagia and excessive drooling and regression of speech. None of the patients had seizures. Patients showed similar biochemical profile with high serum ALT, raised CSF neopterins and abnormal overexpression of interferon stimulated genes. Additionally, all the patients showed generalized changes mimicking cerebral atrophy on brain MRI. This presentation could indicate a genetic type 1 interferonopathy, but all patients were negative for the known genes. Importantly, they demonstrated a clear response to immunotherapies with complete normalisation of the MRI appearances in all patients and normalization of ISGs in patients 1 and 2. Patient 2 also showed normalization of CSF neopterins. Patient 3 still has mildly abnormal ISGs and raised CSF neopterins and therefore she continues on IVIG treatment. The increased ALT also normalized in all patients after a few months.

A notable difference between patient 1 and 2 is that brain biopsy in patient 1 showed only evidence of gliosis whereas biopsy in patient 2 showed clear evidence of inflammation as well as tubuloreticular inclusions. This may reflect different timings of biopsies from symptom onset. On the other hand, it has been previously reported that in severe inflammatory brain disorders gliosis without evidence of inflammation can be the only histopathologic finding. Tubuloreticular inclusions on ultrastructural examination have been shown to be related to the presence of excessive interferon. In addition to type 1 interferonopathies their presence has been linked to systemic lupus erythematosus and viral infections. No evidence of these conditions was found in our patients. (REF) One cannot exclude the possibility of a slow infectious encephalitis, from a potential unknown agent (viral or other). However, the improvement with steroids makes this highly unlikely and deep RNA sequencing for viruses in brain tissue was negative.
We believe that patient 1’s abnormally low complex IV on respiratory complex analyses is either secondary or spurious, as complex IV is the most sensitive of the assays to sample handling. Furthermore, no other evidence of a mitochondrial disorder was found on biochemical or genetic testing.

Rasmussen encephalitis presenting with slowly progressing hemiparesis without seizures has been reported. However, the bilateral presentation seen in our cases makes this diagnosis unlikely. A diagnosis of an antibody mediated encephalitis could be considered. The authors believe that this is also unlikely as no neuronal antibody has been identified and our patients’ prolonged regression is not typically seen in these disorders. Nevertheless, the improvement in patient 3 with mainly only IVIG leaves the possibility of an unidentified antibody mediated encephalitis open.

All patients were treated with pulse IVMP and IVIG and demonstrated a quick and substantial clinical improvement in their motor function, bulbar symptoms and expressive language skills in the following months after treatment. All 3 patients showed relentless deterioration for several months and improvement was immediately noticed within days of treatment which makes the improvements observed unlikely to be part of the natural history of this disorder. The mechanisms of action of both IVIG and steroids may go beyond the known immunosuppressive and immunomodulative effect and may also be beneficial in patients with primary genetic conditions and secondary inflammation.

The milder systemic manifestation seen in the brother of patient 2 raised the possibility of an underlying genetic disorder. Nevertheless, he has remained neurologically asymptomatic over the following years. Several monogenic disorders mimicking acquired diseases have been described such as RANBP2 and DARS and some may respond to immunotherapy. Although the phenotype of our patients is not in keeping with these known disorders we cannot rule out a yet undiscovered monogenic disorder. Alternatively, as previously reported in a child with AGS with acquired NMOSD, these patients could have two different disorders with an underlying genetic predisposition and a second acquired insult.

We highlight the importance of evaluating children presenting with neurodegeneration of unknown aetiology for CNS inflammation, assessing both innate and adaptive immunity biomarkers. Immunotherapy should be considered in children presenting with this distinct phenotype of subacute neuroregression, imaging appearances mimicking brain atrophy and evidence of innate immune activation. This may reverse the course of the disease as exemplified by our cases.
Acknowledgment

We are very grateful to the patients’ families for providing the videos and consenting for us to report their cases. We are also grateful to: Dr Carlos DeSousa, Professor Yanick Crow and Dr Despina Eleftheriou for their thoughtful comments on the manuscript; Dr Gillian Rice for performing the ISG assays and for providing the relevant graphs; Dr Manju Kurian for performing whole exome sequencing in for patients 1 and 2. In addition, we would like to thank all the numerous allied health professionals caring for these children during their complex course of disease.

Reference

Figure 1 capture:
Brain MRI axial T2 images. **A:** Case 1 at 32 months (12 months after reported symptom onset): Bilateral ventricular and sulcal prominence evidencing volume loss. **B:** Case 1, 26 months after treatment: Complete reversal of previous changes. **C:** Case 2 at 5 years (5 months after reported symptom onset): Generalized volume loss more evident the right cerebral hemisphere. **D:** Case 2, 23 months after treatment: Significant reversal of the previously noted appearances of ventricular and sulcal prominence. **E:** Case 3 at 4 years (9 months after reported symptom onset): Slight reduction in the cerebral and cerebellar white matter bulk. **F:** Case 3, 13 months after treatment: Improvement of white matter bulk.

Figure 2 capture:
The figure shows the white matter from Case 2. There is a collection of chronic inflammatory cells (A-H&E), confirmed as a mixture of T-cells (B-CD3) and microglia (C-CD68) by immunohistochemistry. On ultrastructural examination by electron microscopy (D-EM), there were frequent tubuloreticular inclusions (arrow) in the endothelium. Scale bars: A, B & C 100nm D-500nm

Figure 3 capture:
Quantitative reverse transcription–polymerase chain reaction of a panel of six interferon stimulated genes (ISGs) in whole blood measured in the three patients and the brother of patient two compared with healthy control. The relative quantification (RQ) value is equal to $2^{-\Delta\Delta Ct}$, with $\Delta\Delta Ct \pm$ SDs (ie, the normalized fold change relative to a calibrator). Evidence of marked upregulation of type I interferon signaling was observed in all three patients and in patient’s two brother. There was normalization of ISGs in patients 1 and 2 after treatment. Age at sampling: **Case 1**, **purple bars**: 3 years and 3 months (pre-treatment); 4y8m (post-treatment). **Case 2**, **red bars**: 5y3m; 5y4m; 5y5m; 5y9m (pre-treatment); 6y; 6y2m; 6y10m (post-treatment). **Case 2’s brother**, **light blue bars**: 1y3m; 2y; 2y8m. **Case 3**, **green bars**: 4y7m; 5y (pre-treatment); 5y3m; 5y7m (post-treatment). Arrows under the X axis indicate treatment initiation.

Video 1 capture
Video 1: A video clip of the patient in Case 1 taken in four different time points. **First clip** at age two years and eleven months shows dystonic posturing of both upper limbs and difficulty to grasp objects. He also had some degree of axial hypotonia with curving of the spine. **Second clip** at age four years with obvious dystonic posturing and movements of all four limbs with both feet on equinovarus position. **Third and fourth clip** at age four years and a half after treatment shows him playing with toy and tablet computer with better upper limb posturing, grasp and fine motor skills.

Video 2 capture
Video 2: A video clip of the patient in Case 2 taken in two different time points. **First clip** at age six years and six months after treatment was started still presenting with abnormal gait pattern with increased tone and bilateral dragging her feet more marked on the left side (this was already improved compared to presentation). **Second and third clips** at age eight years walking up and down the stairs independently with an improved gait and riding a bicycle without any difficulties.

Video 3 capture:
Video 3: A video clip of the patient in Case 3 taken in four different time points. **First clip** at age four years mainly showing the complete loss of expressive speech. **Second clip** at age four
years and six months shows a spastic/dystonic gait characterized by a wide base, hyperextended knees and feet posture into equinovarus. She was only able to walk independently for a few seconds. Third clip at age five years and eleven months shows some dystonic posturing while grasping but already with significant improvement compared to pre-treatment state. Fourth clip at age six years and four months shows her independent gait with internal rotation of both feet, more noticeable on the right side.
<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brain MRI</strong></td>
<td>Progressive right hemispheric evolving to global symmetric volume loss. Two years after treatment: complete reversal of changes.</td>
<td>Generalized cerebral volume loss more marked in the right cerebral hemisphere. Three years after treatment: reversal of MRI changes.</td>
</tr>
<tr>
<td><strong>Brain histology</strong></td>
<td>Patchy gliosis with good neuronal preservation and no significant inflammation.</td>
<td>Perivascular lymphocytes; focal collections of inflammatory cells in the white matter. Ultrastructural examination: frequent tubuloreticular inclusions in the endothelium.</td>
</tr>
<tr>
<td><strong>Serum</strong></td>
<td>ALT maximum: 90 U/L</td>
<td>ALT maximum: 393 U/L</td>
</tr>
<tr>
<td><strong>CSF neopterin</strong></td>
<td>240 and 355 nmol/L (7-65 nmol/L), not repeated after treatment</td>
<td>200 nmol/L (7-65 nmol/L), repeated 24 months after treatment: 29 nmol/L</td>
</tr>
<tr>
<td><strong>Genetics</strong></td>
<td>Whole exome sequencing: no changes to the genes responsible for interferonopathies, mitochondrial disorders, neurotransmitter disorders, early onset parkinsonism, dystonia disorders and neurodegeneration with brain iron accumulation.</td>
<td>Whole genome sequencing ongoing: no changes identified so far.</td>
</tr>
<tr>
<td><strong>Other investigations</strong></td>
<td>All patients showed: no cells, normal proteins in CSF; oligoclonal bands negative in serum and CSF; testing for antibodies as associated with autoimmune encephalitis and serology screening for infections negative; normal electroencephalograms.</td>
<td>---</td>
</tr>
<tr>
<td><strong>Liver and muscle biopsies:</strong></td>
<td>Normal, low complex IV in patient 1 (muscle), see text</td>
<td>---</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>18 months from clinical presentation: - IV Methylprednisolone (30mg/kg), 6 weekly pulses followed by IV Immunoglobulin (2g/kg), monthly.</td>
<td>12 months from clinical presentation: - IV Methylprednisolone (30mg/kg, 5 days) and IV Immunoglobulin (2g/kg), 4 cycles, 3 months apart.</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>Improvement mainly in fine motor, non-verbal communication. Also, gross motor skills and speech. Able to sit unsupported and gaining new vocabulary.</td>
<td>Significant improvement in movement disorder and in all domains of function: gross motor, fine motor and speech.</td>
</tr>
</tbody>
</table>
Time from reported symptom onset

- 12 months
- 5 months
- 9 months

Time from treatment start (time from reported symptom onset)

- 26 months (44 months)
- 23 months (35 months)
- 13 months (30 months)
Conflicts of Interest

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from marios.kaliakatsos@gosh.nhs.uk

Signed by all authors as follows:

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Mario Sa</td>
<td></td>
</tr>
<tr>
<td>2. Yael Hacohen</td>
<td></td>
</tr>
<tr>
<td>3. Kling Chong</td>
<td></td>
</tr>
<tr>
<td>4. Glenn Anderson</td>
<td></td>
</tr>
<tr>
<td>5. Thomas S Jacques</td>
<td></td>
</tr>
<tr>
<td>6. David Neubauer</td>
<td></td>
</tr>
<tr>
<td>7. Elzbieta Szczepanik</td>
<td></td>
</tr>
<tr>
<td>8. Ming Lim</td>
<td></td>
</tr>
<tr>
<td>9. Marios Kaliakatsos</td>
<td></td>
</tr>
</tbody>
</table>